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The identification of the Duchenne muscular dys-
trophy gene and protein in the late 1980s led to
high hopes of rapid translation to molecular ther-
apeutics. These hopes were fueled by early reports
of delivering new functional genes to dystrophic mus-
cle in mouse models using gene therapy and stem cell
transplantation. However, significant barriers have
thwarted translation of these approaches to true ther-
apies, including insufficient therapeutic material (eg,
cells and viral vectors), challenges in systemic deliv-
ery, and immunological hurdles. An alternative ap-
proach is to repair the patient’s own gene. Two inno-
vative small-molecule approaches have emerged as
front-line molecular therapeutics: exon skipping and
stop codon read through. Both approaches are in
human clinical trials and aim to coax dystrophin pro-
tein production from otherwise inactive mutant
genes. In the clinically severe dog model of Duch-
enne muscular dystrophy, the exon-skipping ap-
proach recently improved multiple functional out-
comes. We discuss the status of these two methods
aimed at inducing de novo dystrophin production
from mutant genes and review implications for
other disorders. (Am J Pathol 2011, 179:12–22; DOI:
10.1016/j.ajpath.2011.03.050)
12Dystrophin Replacement: From the Outside,
or Inside?
Duchenne muscular dystrophy (DMD) is the most com-
mon neuromuscular disease and affects all world popu-
lations equally. The cause of this genetic disease is loss
of a single protein, dystrophin, in all types of muscle (ie,
skeletal, cardiac, and smooth) and in neurons.1,2 The
loss of protein function is the consequence of mutations
in the large DMD gene. The gene contains 79 exons
distributed over 2.3 million bp of genetic real estate on
the X chromosome; however, only approximately 14,000
bp (1%) is used for translation into protein (coding
sequence).3 The 99.5% of intronic junk must be spliced out
of the 2.3 million bp initial heteronuclear RNA transcript to
lead to the mature 14,000 bp mRNA that includes all key
information for dystrophin protein production. Patients with
DMD have mutations in the gene that prevent the appropri-
ate construction of the mRNA and/or the production of the
dystrophin protein, and all patients with DMD show marked
dystrophin deficiency in their muscle.4
During the past 25 years since gene and protein iden-
tification, dozens of innovative experimental therapeutic
approaches for DMD have emerged; many are transition-
ing to clinical trials. These include slowing the progres-
sion of the disease by immune modulators (eg, steroids
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introducing proteins that may compensate for dystrophin
deficiency in the myofiber (eg, utrophin, biglycan, and
laminin), or bolstering the muscle’s regenerative re-
sponse (eg, myostatin and activin 2B). A parallel ap-
proach places dystrophin back into patient muscle.
There are two general tactics to introducing dystrophin
back into dystrophin-deficient muscle: introducing a new
more functional gene into the patient or repairing the
patient’s own gene in some manner. Gene therapy using
viral vectors5,6 and stem cell transplants7 has been used
for exogenous gene delivery. Despite extensive re-
search, including limited clinical trials,8,9 these ap-
proaches have failed to produce clinically significant lev-
els of dystrophin in the muscle of patients with DMD. Key
obstacles include delivery problems [ie, getting the stem
cell or viral vector to the right place in the large target
organ (muscle)], immunological barriers, and production
issues (obtaining adequate amounts of cells or viruses to
treat a patient). Therefore, clinical progress in gene ther-
apy and cell transplantation has been slow.
On the other hand, approaches to coax dystrophin
production out of the patient’s own disabled gene have
been more impressive. A key to the more rapid advance
is the development of small-molecule drugs for gene
repair that overcome problems with target organ delivery,
production, and immune response.
In this review, we discuss progress and the remaining
hurdles in small-molecule drug approaches for gene re-
pair in DMD.
Turning Duchenne into Becker: Exon Skipping
With the characterization of the dystrophin gene, it was
quickly recognized that patients with a clinically milder
dystrophy, Becker muscular dystrophy, showed muta-
tions of the same dystrophin gene as boys with Duch-
enne dystrophy.10,11 The molecular explanation for the
often dramatic clinical differences was framedness. Al-
though the muscle of patients with DMD could not put
together what was left of the dystrophin gene into a ser-
viceable (translatable) mRNA (it was out of frame), pa-
tients with Becker dystrophy had mutations in which the
rest of the gene could still be used effectively and pro-
duce translatable mRNA (in frame).
A model for therapeutics emerged in which a patient
diagnosed as having clinically severe DMD might be
converted to having the milder Becker dystrophy at the
molecular level, by restoring the framedness [eg, turning
an out-of-frame mutation into an in-frame (multiple of
three) mutation]. This occurred spontaneously in some
patients with DMD who appeared to have a frameshift
nonsense mutation on genomic DNA but were able to
rescue some dystrophin production by skipping an ad-
ditional exon, bringing the resulting mRNA back into
frame.12–14 The same spontaneous exon-skipping pro-
cess is observed in many muscle biopsy specimens from
patients with DMD and in mdx mouse muscle in the form
of revertant fibers [ie, a small proportion (1%) of strik-ingly positive myofibers in a background of complete
dystrophin deficiency].15–17
The therapeutic strategy using this concept was dubbed
exon skipping, in which antisense oligonucleotides (AOs)
were designed to modulate the splicing of the dystrophin
gene of a patient with DMD, resulting in mRNA transcripts
that are Becker-like (ie, able to make some level of func-
tional dystrophin) (Figure 1). AOs are short nucleic acid
sequences designed to selectively bind to specific mRNA
or pre-mRNA sequences to generate small double-
stranded regions of the target mRNA. By binding to these
critical regions and forming double strands at key sites
where the spliceosome or proteins of the spliceosome
would normally bind, the mutated (frameshifting) exons are
skipped and the remainder of the pre-mRNA is edited cor-
rectly in frame, albeit shorter. AOs were designed to target
specific exons (eg, exon 51 drug PRO051 in Figure 1) and
tested in the mdx mouse model19,20 and then in cultures of
muscle from patients with DMD.21 In these systems, they
diffused into the dystrophic myofibers and then into the
nucleus, where they bound the unspliced pre-mRNA, mod-
ulated splicing, and restored dystrophin expression.
Why Do AOs Work Better in DMD Compared
with Other Previous Clinical Applications?
Antisense drug development for human disease has
been pursued for approximately 20 years, and AOs have
been tested clinically in 90 clinical trials (http://www.
clinicaltrials.gov/ct2/results?termantisense, last ac-
cessed March 1, 2011). Of these trials, 40 have been
completed, involving 2000 patients, targeting can-
cer, inflammatory disease, and other indications.22,23
Despite this impressive effort, only one AO has been
approved by the Food and Drug Administration (Vit-
ravene, an intraocular injection to inhibit cytomegalo-
virus retinitis in immunocompromised patients; Isis
Pharmaceuticals, Carlsbad, CA), and this drug is no
longer marketed.
Why have so many of the AO drug programs failed,
and why might AO treatment in DMD work better? Excel-
lent literature reviews have indicated the significant bio-
logical barriers to antisense efficacy, including uptake
and sequestration in the reticuloendothelial system, sig-
nificant barriers to achieving sufficiently high intracellular
concentrations in target cells because of endothelial,
basement membrane, and cell membrane barriers, and
intracellular sequestration in phagolysomes or in oligo-
protein complexes. In addition, there is the challenging
requirement that to produce pharmacological activity, a
large fraction of many RNA targets needs knocking down
(90%) before biochemical efficacy is realized.24 For
DMD, the disease itself seems to have navigated some of
these major hurdles, with a dramatic improvement in bio-
chemical efficacy relative to other indications. There are
two key differences with AO applications to DMD, and
these result in an approximate 100-fold improvement in
efficacy compared with previous AO applications. First,
AO drugs in all other indications are designed to knock
down (inhibit) the target, whereas the goal in DMD is to
sma me
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membranes of DMD muscle are leaky as a result of the
underlying pathophysiological features, facilitating a
route of entry for AOs into myofibers.25 Indeed, i.v.deliv-
ered AO’s show very poor delivery to normal muscle,
while dystrophic muscle or i.m. injection in normal muscle
shows excellent delivery (Figure 2).26
Regarding previous knockdown AO approaches, it
is approximately 10 times harder to effectively knock
down a target than it is to knock up a target (as in
DMD). In a knockdown model, the goal is to take 100%
of the protein down to approximately 10% to achieve
the desired biochemical loss of function. For example,
in cancer, where an oncogene is targeted by an AO,
the AO would need to bind approximately 90% of the
mRNA target to bring protein expression down to 10%
and oncogenic transformations are generally not a sin-
gle-gene disorder. For DMD, the goal is to restore
expression of the target gene to 10%, but this trans-
lates into needing to hit only approximately 10% of
mRNA targets with the drug (bringing protein expres-
sion from 0% to 10%). Thus, knockdowns need to hit
90% of targets, but DMD knock ups need to hit only
Figure 1. Mechanism of action of AO exon-skipping drugs. A: Dystrophin ge
maintain the protein translational reading frame (only exons 48 to 53 are shown
together, but there is a disruption of the reading frame, disabling the ability of t
muscle and unstable plasma membranes. CK indicates creatine kinase. C: The m
(adjacent to the missing exon 50 sequence) is skipped, so that the mRNA sp
Becker-like dystrophin, resulting in partial repair of the myofiber pla
Massachusetts Medical Society).1810% of targets (a 10-fold difference).Then, there is an additional advantage of dystrophic
muscle providing easier access for the AO into myofi-
bers. All previous AO applications have had trouble
achieving adequate concentrations of drug within the
cell. The major barrier to AO drugs is the cell plasma
membrane. AOs typically do not traverse membranes
well, and efforts to make the drugs more cell perme-
able tend to increase toxicity. Patients with DMD have
unstable plasma membranes in their muscle fibers,
which effectively provide a leaky entry for drug delivery
(Figure 1). Although it is challenging to quantify this
delivery advantage in DMD muscle, the cell permea-
bility defect may increase drug delivery by a factor of
10. Consistent with this model of unstable membrane
delivery, systemic AOs delivered to healthy muscle do
not show effective delivery, indicating that the dystro-
phic process is a requirement for sufficient drug deliv-
ery (Figure 2).
Taken together, the 10-fold increase in cell delivery
because of unstable membranes and the 10-fold re-
laxed requirements for hitting mRNA targets cumula-
tively give AO used in DMD a 100-fold advantage com-
ing in healthy muscle, in which all 79 exons are precisely spliced together to
patient with DMD with a deletion of exon 50. The remaining exons are spliced
A to produce any dystrophin. Consequently, there is a dystrophin deficiency in
sm of action of PRO051, an AO drug targeting exon 51. The exon 51 sequence
n 49 to 52. The new deletion is able to be translated into semifunctional
mbrane. Reproduced with permission from Hoffman (copyright 2007,ne splic
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Safety
Organisms have fairly sophisticated inflammatory re-
sponses directed against exogenous DNA or RNA. Ge-
Figure 2. Morpholino AOs achieve myofiber delivery through bulk flow across
unstable plasma membranes. Many publications have shown that morpholinos
delivered i.v. achieve unexpected efficacy for modulating splicing within dys-
trophic myofibers, presumably through bulk flow across unstable dystrophic
plasma membranes. Herein, we test this model using i.v. versus i.m. delivery of
a morpholino in healthy murine muscle. A: 0 mg (water) or 1 or 4 mg morpho-
lino was given in an i.v. bolus in healthy mice, and drug delivery to myofibers
was assayed by exon skipping in the Akt1 mRNA (skipped Akt1). No detectable
exon skipping was observed in healthy skeletal muscle (0%). B: As a positive
control, the same morpholino was delivered by i.m. injection in saline (0, 0.1, 1,
10, and 100 g). The saline destabilizes the myofiber membranes, and efficient
dose-related exon skipping is observed (skipped Akt1). GAPDH indicates glyc-
eraldehyde-3-phosphate dehydrogenase.
Figure 3. Backbone chemistries of nucleic acids and antisense drugs. No
linkages, and one of four bases (G, A, T, C for DNA and G, A, U, C for RNA) i
nucleic acid strands. The AO drug chemistries modify the backbone to mak
ribose ring and a sulfur residue to the phosphodiester linkage. The morp
nitrogenous morpholine ring; amine groups replace the phosphodiester linkage. D
spacing between the bases is similar to DNA and RNA and does not disrupt base pnetic material coming into the body from the outside is
assumed to be infectious; as a result, DNA or RNA is
immunostimulatory or proinflammatory. Oligonucleotides
activate innate immunity, with single-stranded oligonucle-
otides binding to toll-like receptor 9 or other receptors of
innate immunity. This binding tends to be both sequence
and chemistry dependent.27 Thus, AO drugs must be
disguised in a way to circumvent surveillance and inflam-
matory responses. Typically, this is accomplished by
avoiding CG motifs that are more common in bacterial
DNA and by using medicinal chemistry that keeps the G,
A, T, and C bases the same (so they can bind to the
target sequence) but replacing the ribose-phosphodi-
ester backbone with different chemistries (Figure 3) that
evade immune surveillance. In addition, medicinal chem-
istry can be used to further enhance cell uptake. In gen-
eral, increasing the charge of the backbone increases pro-
tein binding, including cell surface binding, making it more
likely that the AOs get into cells. However, increased charge
can also make AOs more toxic, often through facilitating
interactions with other proteins (eg, the tenase complex
of intrinsic clotting cascade28 or factor H in the alternative
complement cascade).29 In DMD, the need to increase
charge to enhance delivery is ameliorated (AOs do not have
the same cell delivery problem as in other disorders) be-
cause there is already a leaky gateway into the cell. There
are two commonly used backbone chemistries that are
being used in the development of AO for DMD, one
charged and the other uncharged (described later), and
each has its pros and cons.
2=-O-Methyl Phosphorothioate
Candidate drugs using this chemistry keep the ribose
ring intact but add moieties to both the ribose ring and
the phosphodiester linkage between riboses in the AO
chain. This is the chemistry of choice in the Prosensa/
GlaxoSmithKline DMD drug development program
(Prosensa Therapeutics, Leiden, the Netherlands). The
toxicity and clinical safety of phosphorothioate oligo-
nucleotides as a class have been well characterized in
preclinical studies and human clinical trials of candi-
A and RNA has ribose rings (sugar moieties) attached by phosphodiester
d to the ribose and participates in sequence-specific base pairing with other
ugs more stable and less toxic. The 2=OMe AO adds a methyl group to the
(PMO) chemistry makes many more changes, replacing the ribose with armal DN
s attache
e the dr
holinoespite the relatively dramatic chemical changes to the PMO backbone, the
airing with other nucleic acid strands.
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Some of these studies have used modification of the 5=
and 3= ends, with 2=-O-methoxy ethyl–modified ribose
to make the drugs more resistant to degradation by
nucleases. AOs can prolong the intrinsic clotting path-
way (activated partial thromboplastin time) and in-
crease complement split products in the monkey, but
this appears to be dose dependent, with clinically sig-
nificant levels occurring at relative high plasma peak
concentrations (50 g/mL).35 Human phase 1 safety
studies have shown concentration-dependent effects
on coagulation and complement, with the maximum
tolerated dose by 24-hour infusion being approxi-
mately 20 mg/kg.36 The observed adverse effects ap-
pear to be transient. Similar to other 2=-substituted
AOs, the most prominent end-organ finding for phos-
phorothioate AOs in the monkey has been the pres-
ence of granules in the proximal tubular epithelial cells
of the kidney, most likely from the uptake by phagocy-
tosis of filtered oligonucleotide.37 Regarding applica-
tions to DMD, phosphorothioate chemistries (2=OMe)
have the great advantage of extensive preclinical and
clinical experience.
Morpholino
This is the chemistry of choice in the AVI BioPharma DMD
program (AVI BioPharma, Bothell, WA). The key advan-
tage of the morpholino chemistry compared with phos-
phorothioate is the superior therapeutic window. Morpho-
lino AOs have been dosed i.v. in monkeys to 320 mg/kg
per week and in rodents to 960 mg/kg per week, with no
evidence of dose-limiting toxicities.38 As noted later, the
2=OMe drug PRO051 showed proteinuria at 6 mg/kg per
week using s.c. doses in patients with DMD, whereas a
similar morpholino drug showed no proteinuria at doses
to 320 mg/kg per week using i.v. delivery in monkeys.
The major disadvantages are the much lower clinical
experience with morpholino chemistry. There have been
three clinical trials completed involving 39 patients with
morpholino antisense, compared with 40 trials and 2000
patients in completed trials with other antisense AO
chemistries (http://www.clinicaltrials.gov).
Phosphorodiamidate morpholino oligomers (PMOs)
are a class of backbone modification that has a mor-
pholino ring as a replacement for the furanose, with
phosphorodiamidate linkage connecting the morpho-
lino nitrogen atom with the hydroxyl group of the 3= side
residue (Figure 3). This backbone modification sets
this class of AOs apart from most other modifications,
and the synthesis of these AOs is unique. Until re-
cently, this chemistry was not in the public domain for
therapeutic applications. As a result, only modest
progress has been made in improving the purity, ca-
pacity, and cost of goods for these AOs.
AOs synthesized from morpholinos retain high sequence
specificity and strong binding to the target RNA. They are
sufficiently dissimilar from native RNA and DNA in that they
are not recognized by host RNA or DNA or degrading
enzymes, thus making them more stable. In animal models,
AOs synthesized from morpholinos (PMOs) do not causecomplement activation at high serum concentrations after
repeated (weekly) i.v. administration (approximately 1 g/kg
per week i.v.; AVI BioPharma poster, http://www.avibio.com/
wp-content/uploads/2010/10/AVI-4658-WMS-Preclin-Poster-
101510.pdf, last accessedMarch 1, 2011). PMOs are highly
water soluble, are not subject to metabolic degradation,
and do not activate the toll-like receptors, the interferon
system, or the NF-B–mediated inflammation response.39
Toxicity studies have been performed in both mouse (12
weekly i.v. or s.c. injections to 960 mg/kg per dose) and
monkey (12 weekly i.v. or s.c. injections to 320 mg/kg per
dose). No evidence of liver or kidney dysfunction was seen,
although there was histological evidence of accumulation in
the proximal renal tubules, a finding seen with most AOs.
Clinical trials of PMOs are under way in the UK and are
about to begin in the US; thus, clinical safety data for DMD
are limited.
Additional Chemistries and Technologies for
Exon Skipping
Although the approaches previously described are
promising, alternative strategies are being developed
to address some potential limitations. Alternatives in-
clude the development of methods and chemistries to
i) increase potency to reduce the amount of drug that
will need to be manufactured and delivered to patients;
ii) permit delivery to nonskeletal muscle target tissues,
such as the heart; and iii) mitigate the need for re-
peated parenteral administration (eg, weekly or
monthly i.v.).
One approach is to increase the charge of the AO
through addition of residues along the backbone or at either
end. Examples of modifications of the end of the AO include
the peptide-modified PMO or morpholino40 and guanidium
dendrimer (vivo morpholino).41 Another approach is to add
targeting peptides (ie, small amino acid sequences that can
interact with the muscle fiber membrane).42,43
Although each of these modifications to the backbone
increases potency, the modifications also tend to bypass
the holes in membrane delivery that unstable DMD mem-
branes afford and, thus, lose this disease-specific advan-
tage in DMD. They also tend to increase toxicity because
they may bind to plasma proteins or cell surface proteins
on nonmuscle cells (or vasculature or blood cells) and
generate undesired off-target effects. Although alterna-
tive chemistries will be a continued focus for research, it
is likely that efficacy in DMD will first be proved using the
existing PMO and 2=OMe chemistries.
Another alternative approach is to perform exon skipping
using gene therapy instead of AOs.44–46 Herein, specific
mRNA splicing molecules (ie, U7 or U1 RNA) are designed
to splice out extra exons; these customized U7 drugs are
coded within gene therapy viral vectors. The muscle is
infected with the virus, the U7 drugs are expressed, and the
drugs work efficiently at driving the desired in-frame spliced
products. A critical advantage of the U7 approach is that
one treatment may last a lifetime because the gene therapy
vectors seem stable in muscle and continue to express the
U7 RNA. A disadvantage of this approach is that it requires
Dystrophin Restoration 17
AJP July 2011, Vol. 179, No. 1viral gene therapy; as previously noted, gene therapy of
DMD has faced persistent hurdles of immune response,
viral production, and systemic delivery.47
Evidence for Efficacy of AO Exon Skipping:
Preclinical and Clinical Studies
Animal Studies
The premise for exon skipping in DMD has been well
studied in the mdx mouse model. In the early part of this
decade, several laboratories established the fact that
delivering sequence-specific AOs can induce exon skip-
ping, which reestablishes the reading frame of dystrophin
mRNA in myogenic cell cultures.19,48–50 After these early
findings, the AOs could be delivered via i.m. injection and
could induce dystrophin expression to near–normal lev-
els in most muscle fibers; this was accompanied by func-
tional improvement.51 Most recently, systemic delivery of
AOs by i.v. injections can induce exon skipping and
dystrophin expression up to levels found in healthy mus-
cle. In addition, after three i.v. injections at weekly inter-
vals, enhanced dystrophin expression was detected in
every skeletal muscle examined.52 Regarding dose-re-
sponse and dosing schedules, single injections at a high
dose (3 g/kg) show robust dystrophin expression and
relatively long persistence of protein rescue.53 These
preclinical data suggest that i.v. delivery might show
good efficacy at a frequency of three to four doses per
year, rather than the weekly doses used in most current
preclinical and clinical studies.
An oft-quoted adage is that academic medicine has
generated thousands of highly efficacious mouse drugs
and far fewer effective human drugs. Demonstration of
efficacy in a large animal model typically engenders
7 865
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Immunostainingmore confidence in human applications. Therefore,work54,55 has been performed in the dog model of DMD
that has a mutation in exon 7 of the dog dystrophin gene.
Dogs with DMD represent a particularly stringent test of
exon skipping, in that: i) they typically show rapidly pro-
gressive disease, often leading to death by 6 months;
ii) the nature of the dog mutation requires skipping of two
exons to bring the transcript back into frame; and
iii) because the dog deletion is near the beginning of the
dystrophin protein (actin binding site), this may be more
biochemically disabling to the protein than more central
deleted regions (Figure 4). In these studies, three morpho-
lino AO drugs were codelivered to dogs with DMD to
achieve exon skipping, using high doses of up to 200
mg/kg i.v. per week.56 Given the size of the dogs, these
studies required production of a large amount of AO drug.
Despite the stringency of the model, all of the three
dogs tested showed stabilization or improvement of mul-
tiple functional, imaging, and histological parameters
(Figure 4). Dystrophin production was increased to an
average of approximately 20% in all skeletal muscles,
and no toxicities were observed despite the high cumu-
lative exposure. The dystrophin amounts varied consid-
erably from muscle to muscle, and, consistent with mu-
rine studies, systemic delivery to the heart was poor.
Clinical Studies
The first human studies were published from a private/
public partnership in Leiden, the Netherlands, between
the university and Prosensa Therapeutics.57 The AO
drug, PRO051, was against exon 51 of the human dys-
trophin (DMD) gene and used phosphorothioate (2=OMe)
chemistry (Figure 1). In a phase 1 safety study completed
in 2007, single i.m. doses of PRO051 were safe and well
tolerated in four patients with DMD who were aged 10 to
10
p) (188 bp)
Morpholino Treated
3AO exon skipping
5 x 120 mg/Kg/wk
Figure 4. Delivery of multiple PMO drugs to a
dog model of DMD skips multiple exons and re-
sults in de novo dystrophin production. A: Sche-
matic of dog gene structure. The sporadic golden
retriever dystrophin gene mutation is a splice-site
mutation of exon 7 (red symbol). This forces the
exclusion of exon 7, whereby the dystrophic dog
muscle splices exon 6 to 8, but these exons do not
share the same reading frame (out of frame). AOs
covering exons 6 and 8 were designed (AOs 1, 2,
and 3) to block inclusion of exons 6 and 8, leading
to in-frame rescued transcripts (exons 5 to 9 or 5 to
10). B: Histological features and matched dystro-
phin immunostaining of AO-treated dystrophic
dogs (right) and controls [nontreated canine X
linked muscular dystrophy (CXMD) muscle; left].
Nontreated muscle shows necrosis of myofibers
and inflammatory cell infiltration, whereas AO-
treated muscle shows no inflammation or necrosis.
Dystrophin protein is absent in the nontreated
muscle, whereas the AO-treated muscle shows
high amounts of membrane dystrophin, compara-
ble to healthy muscle. Adapted with permission
from Yokota et al (copyright 2009, John Wiley &
Sons).569
(129 b13 years and were selected on the basis of mutational
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skipping 51 in their cultured cells in vitro. A biopsy spec-
imen of the injection site that was obtained 4 weeks later
showed evidence of de novo dystrophin expression.
Data from an investigator-initiated clinical trial in Lon-
don, UK, using a single i.m. injection of morpholino AO
(AVI BioPharma) were published in 2009.58 The investi-
gators used an AO sequence that was similar, but not
identical, to that used in the previous Dutch trial but
switched to the newer morpholino chemistry. In this
phase 1 study, AVI-4658 was given to seven patients with
DMD (aged 12 to 18 years) as an i.m. injection in the
extensor digitorum brevis. Two boys received a low dose
of 0.09 mg in 900 L, and five boys received 0.9 mg in
900 L. Each boy received a saline injection in the
contralateral extensor digitorum brevis. Muscle biopsy
specimens were obtained before treatment and at 3 or
4 weeks and examined for dystrophin production. AVI-
4658 was well tolerated, and no dose-limiting toxicities
were observed. Treated patients had evidence of in-
duced dystrophin production in a dose-responsive
manner.
In both i.m. studies, the amount of dystrophin in treated
muscle, measured by immunoblot, was low (approxi-
mately 1% to 5%) versus levels in healthy muscle. Al-
though immunoblotting is a good method for determining
the average levels of dystrophin in the tissue, it has less
sensitivity compared with dystrophin immunostaining,
which is able to identify individual fibers expressing rel-
atively low levels of dystrophin. Work is ongoing to eval-
uate and standardize the optimal methods for use in
clinical trials. In addition, the amount of dystrophin ex-
pression that correlates with clinical response is not es-
tablished. From early genotype-phenotype studies59,60 of
dystrophinopathies, dystrophin immunoblot levels 10%
of normal may be necessary for clinical activity; neither
i.m. study consistently reached this level.
An open-label dose-ranging study61 of the PRO051
2=OMe drug in 12 patients was recently reported. Pa-
tients with DMD were given five weekly s.c. doses, rang-
ing from 0.5 to 6 mg/kg, with muscle biopsy specimens
obtained at both 2 and 7 weeks after the initiation of
treatment. Both the 2- and 7-week biopsy specimens
showed drug-induced dystrophin mRNA splicing and
protein production, although the levels of dystrophin by
immunoblot appeared lower than might be needed for
altering clinical symptoms. There was no clear dose-
response relationship between dystrophin immunostain-
ing and drug doses. All patients were then enrolled into a
12-week extension study using the peak dose (6 mg/kg
per week). At the conclusion of the extension study, pa-
tients seemed to perform better on a 6-minute walk test,
suggesting clinical efficacy. Because biopsy specimens
were not obtained after the 12-week extension study, it
was not possible to correlate molecular efficacy with ap-
parent clinical efficacy; and because the study was open
label and not placebo controlled, the improvement in
functional outcomes needs to be interpreted cautiously.
Nevertheless, this study provided sufficient evidence for
GlaxoSmithKline to initiate a 1-year, phase 3, blinded
placebo-controlled study of 6 mg/kg per week s.c. dos-ing in 180 patients; the study enrolled patients at 14
sites in seven countries as this article was being written
(http://clinicaltrials.gov/ct2/show/NCT01254019?term
duchenne&rank4, last accessed March 1, 2011).
A key issue for success of high-dose antisense drug
delivery is the achievement of a balance of toxicity and
efficacy (therapeutic window). As previously described,
there are well-documented toxicities that limit human
dosing to approximately 20 mg/kg, yet both mouse and
dog studies suggest that 40 mg/kg may be required for
sufficient dystrophin production. In the GlaxoSmithKline/
Prosensa dose-ranging study, all 12 patients enrolled
experienced proteinuria and an elevated urinary 1-mi-
croglobulin level at week 12 of the extension period,
suggestive of kidney toxicity. Renal proximal tubuli accu-
mulate oligonucleotides through drug reabsorption, and
it will be important to monitor kidney toxicity in the ongo-
ing 12-month phase 3 study.
AVI BioPharma has performed a dose-escalation study
in the UK with systemically administered AVI-4658. Al-
though not yet published, data have been presented in
press releases and at meetings. The study included six
cohorts given 12 weekly i.v. doses, ranging from 0.5 to
20.0 mg/kg per dose. At the highest dose, one patient is
reported to have de novo dystrophin production, with
approximately 50% of fibers testing positive for dystro-
phin by immunostaining (AVI BioPharma news release,
http://investorrelations.avibio.com/phoenix.zhtml?c
64231&p-irol-newsArticle&ID1433350&highlight, last acce-
ssed March 1, 2011); however, this likely translates to approx-
imately 20% of total dystrophin muscle content by immuno-
blotting. The response of patients to a similar dose has been
variable, and large interpatient variability may become a
theme inexonskipping. Thereareat least two likely reasons for
differences in interpatient response to a similar dose. First, i.v.
doses are typically calculated based on weight of the patient
(mg/kg); the peak serum dose, at which the drug can perme-
ate through the leaky DMD myofiber membranes, may be
more important. Thus, drug doses may need to be calculated
more by body mass index or some other means of approxi-
mating blood volume, rather than simply by patient weight.
Second, the de novo dystrophin produced by exon skipping is
Beckerlike (not normal); researchers have observed that there
can be remarkable interpatient variability in muscle dystrophin
content, despite patients having the same in-frame deletion.
For example, patients with Becker dystrophy who share a
common exon 45 to 47 deletion can vary widely in the amount
of dystrophin in their muscle by immunoblot and the severity of
the histopathological features (Table 1).62
The preclinical and clinical data available thus far sug-
gest that exon skipping may hold significant promise as a
candidate treatment for DMD (although the response
may be variable). However, these studies are early and
clinical development is ongoing. Prosensa, in partnership
with GlaxoSmithKline, has announced work on AO, tar-
geting additional exons. AVI has an investigational new
drug with the Food and Drug Administration and is
expected to begin enrolling patients in trials in the US
in 2011.
te inten
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Exon skipping in DMD presents some unique challenges
and may serve as a test case for personalized medicine,
in which drugs are customized to a patient’s genetic
fingerprint. The exon 51 drug would only be applicable to
relatively few patients with DMD. Indeed, drugs against
five exons would be needed before even half of the
patients with DMD could be treated with exon skipping.
As each drug is developed, the number of patients avail-
able for that drug becomes smaller, for an already rare
disorder. If each exon is considered a new drug requiring
the full battery of toxicology and preclinical and clinical
studies, then the time for development and costs repre-
sent a significant challenge. Some of the populations are
so small that achieving statistical significance in a clinical
trial will not be possible. Because some mutations will
require simultaneous delivery of multiple drugs, as was
the case with the dog model (Figure 4), the problem is
compounded.
AO drugs in development for DMD have been granted
Orphan Drug Designation by the Food and Drug Admin-
istration, which is designed to facilitate the development
of these (and other) drug candidates.63 This designation
provides certain tax credit and marketing incentives to
sponsors. Although Orphan Drug Designation does not
change the requirements for drug approval, these drugs
may also qualify for a 6-month priority review.64 Although
the challenges are significant (as previously described),
at least two companies have launched clinical trials of AO
products; these products will begin to define the regula-
tory path forward. Also, regulatory and scientific agen-
cies, parent advocates, and academic researchers in the
US and Europe are working to define the key issues and
potential solutions in AO drug development for DMD.
One concept that has received some attention is
based on an assumption that AOs of a given chemistry
will have a common safety profile (preclinical and clinical)
and that they will have a common pharmacokinetic pro-
file. If this turns out to be the case, then cumulative data
on the initial exon-specific drugs may allow a more
streamline preclinical toxicology package. Also, if bio-
markers, such as qualitative dystrophin expression, can
Table 1. Variability in Dystrophin Amount and Severity of Histo
Share the Same In-Frame Deletion
Patient
no.
Age at biopsy
(years)
CPK level
(U/L)
Hist
(s
31 9 9760
32 7 NA
33 1 3000
34 37 2844
35 29 692
36 38 NA
37 43 NA
38 20 9543
39 13 NA
40 59 NA
Data are adapted from Kesari et al.62 The gene mutation was an exo
CPK, serum creatine phosphokinase; NA, not available; , modera
normal controls).be validated and correlated with clinical outcomes ininitial trials, they could hypothetically be used in studies
of later exon-specific drugs (particularly when a given
mutation occurs in a few boys). After the first exon-spe-
cific drugs (eg, two drugs) are subjected to the standard
battery of preclinical and clinical tests, using existing
paradigms for drug approvals in rare life-threatening or-
phan diseases, subsequent exon-specific drugs (and
perhaps multidrug combinations) would be approved,
with a reduced battery of testing. This process reduces
the cost and time to bring all exonic drugs to all patients
with DMD. This concept is similar to the concept used in
the annual release of the influenza vaccine. After ap-
proval of a given manufacturer’s vaccine, in subsequent
years, the seasonal vaccine (often with a composition
that is different from that studied for initial approval) is
released (approved) based on a smaller, but well-de-
fined, set of parameters. Regardless of the pathway to
approval, given that the number of boys with DMD avail-
able for study prelicensure will be limited, it is likely that
postapproval studies and long-term follow-up of treated
patients will be required.
Another issue in AO drug development for DMD is the
selection of clinical trial end points based on an under-
standing of the natural history of DMD and (as previously
discussed) standardized consensus methods for dystro-
phin protein measurement (biochemical outcome mea-
sures). The outcome measure that has previously been
used for drug approval in other areas has been a 6-min-
ute walk test. The TREAT-NMD European network has
formed an international effort with the US Wellstone Cen-
ter network to address clinical outcome measures in clin-
ical trials, and publications are expected within the next
year. One of the issues with the existing test is that it limits
registration trials to ambulatory boys. Additional end
points for boys in most need of treatment (nonambula-
tory) are needed, such that this group of patients can
benefit from participation in clinical trials and so that
nonambulatory boys will be included in the drug approval
process.
Finally, approval of AO drugs for DMD will require
refinements in production and potency. As previously
mentioned, current estimations of the dose and regimen
gical Features in Patients with Becker Muscular Dystrophy Who
logical features
of dystrophy)
Immunoblot
(%) Immunostaining
ild 80 
tely severe 5 
50 
20 
50 
5 
te 5 
ild 30 
tely severe 80 
te 30 
47 deletion for all patients.
sity; , moderately high intensity; , high intensity (similar topatholo
opatho
everity
Very m
Modera
NA
Mild
Mild
Severe
Modera
Very m
Modera
Modera
n 45 toneeded for treatment of a boy with DMD suggest that it
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annual dose of 10 g of AO drug. If we assume that
these doses will be tolerated, the current production
costs of morpholino drugs are high and the GMP produc-
tion capacity is limited. 2=O-methyl chemistries are more
widely available and less expensive. For morpholinos,
one approach to decrease the high cost of production of
large amounts of drug is to increase potency so that less
drug is needed per patient. Some promising approaches
to increase potency have been reported in mouse mod-
els, in which the AOs are modified to more efficiently
enter cells or by codelivery of small molecules or nano-
particles that enhance AO uptake or splicing efficie-
ncy.65–69 However, these drugs show new toxicities rel-
ative to the naked unmodified morpholino backbone; and
it may be challenging to achieve an appropriate thera-
peutic window, despite the higher potency.
Premature Stop Codon Read Through:
Gentamicin and Ataluren (PTC124)
In approximately 10% to 15% of boys with DMD, the
disease is caused by a point mutation that causes a
change in a triplet codon, so that it no longer codes for an
amino acid but instead codes for a stop signal (nonsense
codons UAA, UAG, or UGA). Translation of the dystro-
phin protein is prematurely stopped, and the short frag-
ment is nonfunctional and/or degraded. A promising ther-
apy for nonsense mutation DMD is ataluren (PTC
Therapeutics, South Plainfield, NJ), an orally delivered
small molecule designed to selectively induce ribosomal
read through of premature stop codons but not normal
termination codons. Ataluren was developed after genta-
micin, an aminoglycoside, promoted read through in
mammalian models and in the mdx mouse model but
presented lack of potency and potential toxicity and ad-
ministration issues.70 These proof-of-concept experi-
ments led researchers to use high-throughput screening
methods to identify compounds that suppressed the
early, but not normal, termination codons; and did not
present the potency, toxicity, and administration issues
associated with gentamicin. In mdx mice and muscle cell
cultures from patients, ataluren, a nonaminoglycoside,
promoted dystrophin production in primary muscle cells
in humans and in mdx mice expressing dystrophin non-
sense alleles. In addition, ataluren restored striated mus-
cle function in mdx mice within 2 to 8 weeks of drug
exposure.71
PTC Therapeutics has completed phase 1 clinical trials
with ataluren and is finishing data analysis of its phase 2
studies. In phase 1, ataluren, delivered as a single or
multiple doses, was safe and well tolerated and sup-
ported the initiation of phase 2 trials. A total of 62 healthy
adult male and female volunteers were treated in phase
1.72 In phase 2, 38 patients with DMD were given ataluren
at one of three dose levels for 28 days. The drug was safe
and well tolerated, with infrequent adverse events.
Plasma concentrations correlating to activity in preclinical
models were found at the middle and high doses. In
addition, patients receiving ataluren showed qualitativeincreases in muscle dystrophin expression and reduc-
tions in serum creatinine kinase levels. These patients are
being followed up in an open-label long-term safety
study. In April 2008, a phase 2b study was initiated; by
February 2009, the study had full enrollment by 173 pa-
tients with nonsense mutation DMD at 37 sites in 11
countries. This randomized, double-blind, placebo-con-
trolled study had three arms, with approximately 55 pa-
tients per arm: placebo, low dose (10 mg/kg), and high
dose (20 mg/kg) (PTC Therapeutics, http://www.
parentprojectmd.org/site/DocServer/2010-04-16_Final_
Summary_of_Ataluren_Data_at_AAN.pdf?docID9461,
last accessed March 1, 2011). Inclusion criteria per-
mitted both steroid- and non–steroid-treated patients,
a broad age range, and patients showing both Duch-
enne and Becker phenotypes. As a result, there was
considerable range in disease progression. Neither
drug-treated arm reached significance for the primary
clinical outcome measure (a 30-m increase in the
6-minute walk test), although the low-dose cohort
showed a promising trend toward clinical improve-
ment. Dystrophin data have not been reported, and
there have been no formal announcements of if or how
clinical testing will continue.
Ataluren is in clinical trials for three other genetic dis-
orders: cystic fibrosis (phase 3), hemophilia A and B
(phase 2), and methylmalonic acidemia (phase 2). How-
ever, no new trials are listed for DMD; and the future of
the drug in patients with muscular dystrophy is uncertain.
Summary
Small-molecule drugs to coax dystrophin production from
mutated genes in DMD have emerged as the most prom-
ising molecular therapeutics. Both exon skipping using
AOs and stop-codon read through (PTC124) have en-
tered clinical trials, and preliminary results are encourag-
ing. Both approaches are mutation specific and can be
thought of as personalized medicine. Should clinical ef-
ficacy be demonstrated for exon skipping, then it will be
important to have an efficient path for approval of other
exon-specific drugs in the same class (chemistry) to
bring this to most patients with DMD.
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